PAX5 and acute lymphoblastic leukemia: The detected aberrations included previously reported loss/gains that are related to ALL, such as 9p13.2 loss involving PAX5 in patient no. 2 [12]; 9p21.3 loss involving CDKN2A in 4 patients (nos.